Navigation Links
Salugen's Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis

SAN DIEGO, Oct. 26 /PRNewswire/ -- Salugen, Inc., a personalized health and wellness company presented its research entitled: DNA-customized Genotrim [neuronal dopamine release activator] results in significant reductions in weight, appetite and sugar cravings in an obese population in the Dietary Investigation to Evaluate Treatments (D.I.E.T.) pilot study. Polymorphic gene correlates of Reward Deficiency Syndrome (RDS) at the Second Bruce Ames International Symposium on Nutritional Genomics last week at the University of California, Davis. Over the past two years, Salugen's research around genetics and weight loss has been repeatedly awarded by the nation's largest natural products association. At this meeting, Dr. Kenneth Blum, Chief Scientific Officer of Salugen discussed the nutrigenomics of weight loss, specifically on identifying the genes and nutrients governing cravings and appetite.

According to Dr. Kenneth Blum, the co-discoverer of the gene associated with alcoholism, "This study demonstrates that GenoTrim, a DNA-customized nutritional supplement for weight management, is a potentially effective agent in reducing weight and improving symptomatic RDS behaviors. We are also proposing that for persons possessing candidate reward gene polymorphisms resulting in physiological deficits in brain reward neurotransmitters, utilizing a dopaminergic type d2 receptor agonist, such as GenoTrim, can activate the neuronal release of dopamine in the nucleus acumbens."

In this study over 80 days, GenoTrim demonstrated significant reductions in weight, waist circumference, appetite, and sugar cravings, as well as improvements in energy, and feelings of happiness.

Salugen CEO Brian Meshkin states, "We are honored to be among so many other credible researchers from around the world to present important findings about the use of genetic information to customize nutritional supplementation that demonstrates weight loss and improved health. This study adds to over 10 scientific publications supporting GenoTrim for DNA-customized weight loss. We congratulate the staff at UC Davis for a wonderful conference."

Salugen currently markets DNA-customized nutritional solutions under three brands, GenoTrim(TM) for weight management (, SpaGen(TM) for optimal health and wellness ( and Haveos(TM) for substance abuse attenuation.

About Salugen

Salugen, Inc., a leading personalized health and wellness company, engages in the discovery, development and commercialization of patent-protected genetic tests and companion DNA-customized therapeutics worldwide. With over 30 years of research conducted on the genetic causes and pharmacology of many healthcare concerns, Salugen is a pioneer and leader in delivering personalized medicine. Currently, the Company commercializes nutrigenomic technologies where genetic analysis guides the formulation and delivery of nutritional solutions that are customized to the individual. The company has headquarters in San Diego, CA, with its high-complexity CLIA-certified laboratory services in Los Angeles, CA. For additional information about the company, please visit

SOURCE Salugen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. UW-Madison engineers apply award-winning technology to road building
2. Sprecher Brewing unveils award-winning digital office
3. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
4. Quantitation of the Protein MIA as a Marker for Chondrocytes in Research Samples
5. Control Your siRNA Research
6. Getting Started with MicroRNA Research
7. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
8. Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C
9. Research Organics
10. A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders
11. A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)
Post Your Comments:
(Date:11/30/2015)... MAGDEBURG, Germany , November 30, 2015 /PRNewswire/ ... in Vienna, Austria to be held ... NeuroRehabilitation (ECNR) in Vienna, Austria ... a wholly owned subsidiary of Vycor Medical, Inc. ("Vycor") (OTCQB: ... Internet-delivered NovaVision Therapy Suite at the 3rd European Congress ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... MarkLogic, the Enterprise NoSQL database platform provider, creating a seamless approach to ... Content Intelligence capabilities provide a robust set of semantic tools which create ...
(Date:11/28/2015)... ... November 28, 2015 , ... • Jeon Jin Bio Corp, a ... rodent control solutions , Bird Free, an ... across all sensory modalities including visual, smell, taste and touch, enabling safe, effective avian ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... Program that includes over 2,000 technical presentations offered in symposia, oral sessions, ... and applied spectroscopy, covers a wide range of applications such as, but not ...
Breaking Biology Technology:
(Date:11/16/2015)... SAN JOSE, Calif. , Nov 16, 2015 ... leading developer of human interface solutions, today announced ... new Synaptics TouchView ™ touch controller and ... the architectural revolution of smartphones. These new TDDI ... and include TD4100 (HD resolution), TD4302 (WQHD resolution), ...
(Date:11/10/2015)... 2015  In this report, the biomarkers ... product, type, application, disease indication, and geography. ... are consumables, services, software. The type segments ... efficacy biomarkers, and validation biomarkers. The applications ... development, drug discovery and development, personalized medicine, ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):